Showing results (1921-1930 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|November 17, 2012
Measurement and clinical effect of grey matter pathology in multiple sclerosisJeroen J G Geurts, Massimiliano Calabrese, Elizabeth Fisher, et al.
The Lancet. Neurology|August 13, 2022
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort studyIsabel R A Retel Helmrich, Endre Czeiter, Krisztina Amrein, et al.
The Lancet. Neurology|February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trialRichard B Lipton, Robert Croop, David A Stock, et al.
The Lancet. Neurology|March 27, 2023
Personalised virtual brain models in epilepsyViktor Jirsa, Huifang Wang, Paul Triebkorn, et al.
The Lancet. Neurology|May 30, 2020
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysisRachael I Scahill, Paul Zeun, Katherine Osborne-Crowley, et al.
The Lancet. Neurology|May 30, 2020
Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy developmentRachel Thompson, Sally Spendiff, Andreas Roos, et al.
The Lancet. Neurology|November 19, 2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.
The Lancet. Neurology|November 20, 2022
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trialSilvia Lanfranconi, Elisa Scola, Jennifer M T A Meessen, et al.
The Lancet. Neurology|October 18, 2025
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trialCécile Préterre, Aurélie Gaultier, Michael Obadia, et al.
The Lancet. Neurology|October 18, 2025
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control studyBaayla D C Boon, Yoav D Piura, Christina M Moloney, et al.
Pageof 200